Professor | Jiqin Zhang | Asia Growth Partners

Name	Jiqin Zhang
Contact Information	jqzhang@bio.ecnu.edu.cn
Language ability	Chinese, English
Province	Shanghai

Name

Jiqin Zhang

Contact Information

jqzhang@bio.ecnu.edu.cn

Language ability

Chinese, English

Province

Shanghai

University/Lab Affiliation and Title	East China Normal University
Faculty	Life Sciences
Academic Background & Achievements	2007-2012 PhD: East China Normal University 2009-2010 Joint Training: Beijing Institute of Life Sciences 2003-2007 Bachelor's Degree: Tongji University
Work Experience	2022-present: East China Normal University, Researcher 2016-2022: East China Normal University, Associate Researcher 2012-2016: Shanghai Cancer Institute, Assistant Researcher
Awards	2023: National Natural Science Foundation of China Outstanding Young Scientist 2022: Zijiang Outstanding Young Scholar, East China Normal University 2023: Top 10 Research Progress in Hematology in China, Development and clinical application of non-viral targeted integration CAR-T technology 2023: Important Medical Progress in China 2022, Development of a new generation of CAR-T technology to improve the remission rate of treatment for relapsed refractory non-Hodgkin's lymphoma 2022: Science and Technology Achievement Transformation Contribution Award, Southern Weekend

University/Lab Affiliation and Title

East China Normal University

Faculty

Life Sciences

Academic Background & Achievements

2007-2012 PhD: East China Normal University
2009-2010 Joint Training: Beijing Institute of Life Sciences
2003-2007 Bachelor's Degree: Tongji University

Work Experience

2022-present: East China Normal University, Researcher
2016-2022: East China Normal University, Associate Researcher
2012-2016: Shanghai Cancer Institute, Assistant Researcher

Awards

2023: National Natural Science Foundation of China Outstanding Young Scientist
2022: Zijiang Outstanding Young Scholar, East China Normal University
2023: Top 10 Research Progress in Hematology in China, Development and clinical application of non-viral targeted integration CAR-T technology
2023: Important Medical Progress in China 2022, Development of a new generation of CAR-T technology to improve the remission rate of treatment for relapsed refractory non-Hodgkin's lymphoma
2022: Science and Technology Achievement Transformation Contribution Award, Southern Weekend

Areas of Focus	Development of new generation CAR-T technology using novel gene editing tools Identification and development of new therapies to enhance CAR-T cell function using novel screening methods Development of new generation immune cell therapy techniques using synthetic biology methods
Publications	Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL, Jiqin Zhang et al., 2022 Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study, Jiqin Zhang et al., 2023 Intelligent tunable CAR-T cell therapy leads the new trend, Jiqin Zhang et al., 2023 Let's turn the CAR-T cells ON and OFF precisely, Jiqin Zhang et al., 2022 Interleukin-22 regulates the homeostasis of the intestinal epithelium during inflammation, Jiqin Zhang et al., 2019 EGFR modulates monounsaturated fatty acid synthesis through phosphorylation of SCD1 in lung cancer, Jiqin Zhang et al., 2017 Dysregulated DNA methyltransferase 3A upregulates IGFBP5 to suppress trophoblast cell migration and invasion in preeclampsia, Jiqin Zhang et al., 2017 EGFR regulates iron homeostasis to promote cancer growth through redistribution of transferrin receptor 1, Jiqin Zhang et al., 2016 Dissecting the precise role of H3K9 methylation in crosstalk with DNA maintenance methylation in mammals, Jiqin Zhang et al., 2016 Weak binding to E3 ubiquitin ligase c-Cbl increases EGFRvA protein stability, Jiqin Zhang et al., 2016 S phase-dependent interaction with DNMT1 dictates the role of UHRF1 but not UHRF2 in DNA methylation maintenance, Jiqin Zhang et al., 2011 Enhancing the antitumor immunity of T cells by engineering the lipid-regulatory site of the TCR/CD3 complex, Jiqin Zhang et al., 2023 Engineering of efficiency-enhanced Cas9 and base editors with improved gene therapy efficacies, Jiqin Zhang et al., 2022 Induction of TGF-β receptor I expression in a DNA methylation-independent manner mediated by DNMT3A downregulation is involved in early-onset severe preeclampsia, Jiqin Zhang et al., 2020 UHRF2 promotes intestinal tumorigenesis through stabilization of TCF4 mediated Wnt/β-catenin signaling, Jiqin Zhang et al., 2020 Increasing targeting scope of adenosine base editors in mouse and rat embryos through fusion of TadA deaminase with Cas9 variants, Jiqin Zhang et al., 2018 Cas9-nickase–mediated genome editing corrects hereditary tyrosinemia in rats, Jiqin Zhang et al., 2018 A fusion receptor as a safety switch, detection, and purification biomarker for adoptive transferred T cells, Jiqin Zhang et al., 2017 Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN–glioblastoma in vivo, Jiqin Zhang et al., 2016 Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12, Jiqin Zhang et al., 2015 The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III, Jiqin Zhang et al., 2014 A novel EGFR isoform confers increased invasiveness to cancer cells, Jiqin Zhang et al., 2013 UHRF1 targets DNMT1 for DNA methylation through cooperative binding of hemi-methylated DNA and methylated H3K9, Jiqin Zhang et al., 2013 An elaborate regulation of mammalian target of rapamycin activity is required for somatic cell reprogramming induced by defined transcription factors, Jiqin Zhang et al., 2012 Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice, Jiqin Zhang et al., 2012

Areas of Focus

Development of new generation CAR-T technology using novel gene editing tools
Identification and development of new therapies to enhance CAR-T cell function using novel screening methods
Development of new generation immune cell therapy techniques using synthetic biology methods

Publications

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL, Jiqin Zhang et al., 2022
Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study, Jiqin Zhang et al., 2023
Intelligent tunable CAR-T cell therapy leads the new trend, Jiqin Zhang et al., 2023
Let's turn the CAR-T cells ON and OFF precisely, Jiqin Zhang et al., 2022
Interleukin-22 regulates the homeostasis of the intestinal epithelium during inflammation, Jiqin Zhang et al., 2019
EGFR modulates monounsaturated fatty acid synthesis through phosphorylation of SCD1 in lung cancer, Jiqin Zhang et al., 2017
Dysregulated DNA methyltransferase 3A upregulates IGFBP5 to suppress trophoblast cell migration and invasion in preeclampsia, Jiqin Zhang et al., 2017
EGFR regulates iron homeostasis to promote cancer growth through redistribution of transferrin receptor 1, Jiqin Zhang et al., 2016
Dissecting the precise role of H3K9 methylation in crosstalk with DNA maintenance methylation in mammals, Jiqin Zhang et al., 2016
Weak binding to E3 ubiquitin ligase c-Cbl increases EGFRvA protein stability, Jiqin Zhang et al., 2016
S phase-dependent interaction with DNMT1 dictates the role of UHRF1 but not UHRF2 in DNA methylation maintenance, Jiqin Zhang et al., 2011
Enhancing the antitumor immunity of T cells by engineering the lipid-regulatory site of the TCR/CD3 complex, Jiqin Zhang et al., 2023
Engineering of efficiency-enhanced Cas9 and base editors with improved gene therapy efficacies, Jiqin Zhang et al., 2022
Induction of TGF-β receptor I expression in a DNA methylation-independent manner mediated by DNMT3A downregulation is involved in early-onset severe preeclampsia, Jiqin Zhang et al., 2020
UHRF2 promotes intestinal tumorigenesis through stabilization of TCF4 mediated Wnt/β-catenin signaling, Jiqin Zhang et al., 2020
Increasing targeting scope of adenosine base editors in mouse and rat embryos through fusion of TadA deaminase with Cas9 variants, Jiqin Zhang et al., 2018
Cas9-nickase–mediated genome editing corrects hereditary tyrosinemia in rats, Jiqin Zhang et al., 2018
A fusion receptor as a safety switch, detection, and purification biomarker for adoptive transferred T cells, Jiqin Zhang et al., 2017
Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN–glioblastoma in vivo, Jiqin Zhang et al., 2016
Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12, Jiqin Zhang et al., 2015
The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III, Jiqin Zhang et al., 2014
A novel EGFR isoform confers increased invasiveness to cancer cells, Jiqin Zhang et al., 2013
UHRF1 targets DNMT1 for DNA methylation through cooperative binding of hemi-methylated DNA and methylated H3K9, Jiqin Zhang et al., 2013
An elaborate regulation of mammalian target of rapamycin activity is required for somatic cell reprogramming induced by defined transcription factors, Jiqin Zhang et al., 2012
Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice, Jiqin Zhang et al., 2012

Gene Editing Car-T Technology Crispr/Cas9 Immune Cell Therapy Synthetic Biology Tumor Immunotherapy Clinical Trials Safety And Efficacy Non-Viral Integration Therapeutic Innovation

Jiqin Zhang - East China Normal University

Mingkai Xu - University of Chinese Academy of Sciences

Jiayu Chen - Tongji University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us